Literature DB >> 16796699

Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease?

Andreas P Berger1, Wolfgang Horninger, Jasmin Bektic, Alexandre Pelzer, Robert Spranger, George Bartsch, Ferdinand Frauscher.   

Abstract

OBJECTIVE: To evaluate prostatic vascular resistance by measuring the resistive index (RI), and flow velocity using colour Doppler ultrasonography (CDUS), in normal prostates and in patients with benign prostatic hyperplasia (BPH) or prostate cancer, as BPH is considered to be a result of urogenital ageing and studies suggest that hyperplasia in the stromal and glandular compartments might be induced by stromal growth secondary to hypoxia, which in turn results from abnormal blood flow patterns. PATIENTS, SUBJECTS AND METHODS: Ninety-two men (22 with normal prostates, 45 with BPH and 25 with prostate cancer; mean age 56 years) were prospectively evaluated by CDUS. The RI values for the peripheral, central and transition zones were assessed by one investigator. The diagnosis of BPH and prostate cancer was established from histological findings.
RESULTS: The mean (sd) RI in the transition zone was significantly higher only in patients with BPH, at 0.77 (0.05), vs 0.65 (0.05) in the other two groups. In the peripheral and central zones there was no significant difference in the RI among the three groups. Arterial CDUS flow velocity was increased in the transition zone of patients with BPH, but not in the peripheral and central zones.
CONCLUSIONS: The present results support the hypothesis that an age-related impairment of blood supply to the lower urinary tract might have a role in the development of BPH. Although prostate cancer cannot be excluded by measuring RI, high RI values (>0.75) in the transition zone are indicative of BPH.

Entities:  

Mesh:

Year:  2006        PMID: 16796699     DOI: 10.1111/j.1464-410X.2006.06306.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  19 in total

1.  Do AB0 blood groups affect lower urinary tract symptoms?

Authors:  Erdal Benli; Abdullah Çırakoğlu; Ercan Öğreden; Yasemin Kaya; Ali Ayyıldız; Ahmet Yüce
Journal:  Turk J Urol       Date:  2018-11-19

2.  Elevated body mass index correlates with higher seminal plasma interleukin 8 levels and ultrasonographic abnormalities of the prostate in men attending an andrology clinic for infertility.

Authors:  F Lotti; G Corona; G M Colpi; E Filimberti; S Degli Innocenti; M Mancini; E Baldi; I Noci; G Forti; L Adorini; M Maggi
Journal:  J Endocrinol Invest       Date:  2011-07-07       Impact factor: 4.256

Review 3.  Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.

Authors:  Selim Cellek; Norman E Cameron; Mary A Cotter; Christopher H Fry; Dapo Ilo
Journal:  Nat Rev Urol       Date:  2014-03-11       Impact factor: 14.432

4.  Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

Authors:  Emma H Allott; Ilona Csizmadi; Lauren E Howard; Roberto L Muller; Daniel M Moreira; Gerald L Andriole; Claus G Roehrborn; Stephen J Freedland
Journal:  BJU Int       Date:  2019-09-27       Impact factor: 5.588

Review 5.  Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.

Authors:  Stefan Uckert; Matthias Oelke
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

6.  Office evaluation of male patients with lower urinary tract symptoms.

Authors:  Shahin Tabatabaei; Saman Shafaat Talab; Mahdi Zangi; Henry H Woo
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

7.  Impact of preoperative haemoglobin concentrations on the efficiency of KTP-laser vaporization of the prostate.

Authors:  Stephan Buse; Christian Gilfrich; Gencay Hatiboglu; Johannes Huber; Jens Bedke; Jesco Pfitzenmaier; Axel Haferkamp; Markus Hohenfellner
Journal:  World J Urol       Date:  2009-01-15       Impact factor: 4.226

8.  Prostate angiogenesis in development and inflammation.

Authors:  Letitia Wong; Jerry Gipp; Jason Carr; Christopher J Loftus; Molly Benck; Sanghee Lee; Vatsal Mehta; Chad M Vezina; Wade Bushman
Journal:  Prostate       Date:  2013-11-30       Impact factor: 4.104

Review 9.  The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Authors:  Mehmet Umul; Tekin Ahmet Serel
Journal:  Turk J Urol       Date:  2013-12

10.  The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.

Authors:  RenJie Jin; Douglas W Strand; Connor M Forbes; Thomas Case; Justin M M Cates; Qi Liu; Marisol Ramirez-Solano; Ginger L Milne; Stephanie Sanchez; Zunyi Y Wang; Dale E Bjorling; Nicole L Miller; Robert J Matusik
Journal:  Prostate       Date:  2021-07-20       Impact factor: 4.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.